PLANTATION, Fla., July 31 /PRNewswire-FirstCall/ -- Viragen, Inc. (AMEX:VRA) today announced that the Company has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) for a secondary offering of Units, each Unit consisting of one share of common stock and one common stock purchase warrant.
Dawson James Securities, Inc. will act as the lead underwriter for the offering. A written preliminary prospectus for the offering, when available, may be obtained directly from: Dawson James Securities, Prospectus Department, 925 South Federal Highway, Boca Raton, FL 33432, Phone: (561) 391-5555.
A registration statement relating to these securities being offered has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Viragen, Inc.: With international operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of cancers and select viral diseases. Our product portfolio includes: Multiferon(R) (multi- subtype, human alpha interferon) targeting a range of cancers and select infectious diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering research on Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
For more information, please visit: http://www.viragen.com/ Viragen, Inc. Corporate Contact:
Douglas Calder, Director of Communications
Phone: (954) 233-8746; Fax: (954) 233-1414
E-mail: The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company's ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made. http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b http://photoarchive.ap.org/ DATASOURCE: Viragen, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or Web site: http://www.viragen.com/
|